Öz
-
Anahtar Kelimeler
Renin angiotensin system direct renin inhibitors aliskiren plasma renin activity
Kaynakça
- Basso N, Terragno NA. History about the discovery of the renin-angiotensin system. Hypertension 2001;38:1246-9.
- Luft FC. A brief history of renin. J Mol Med 2008;86:611-3.
- Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 2008;7:399-410.
- Siragy HM, Kar S, Kirkpatrick P. Aliskiren: news and analy- sis. Nature Reviews Drug Discovery 2007;6:779-80.
- Uresin Y, Mehtar Bozkurt M, Sabirli S, Ozunal ZG. Aliskiren, the future of renin-angiotensin system blockade? Expert Rev Cardiovasc Ther 2007;5:835-49.
- Müller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006;1:221-8.
- Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocar- dial infarction in hypertensive patients. Am J Hypertens 1997;10:1-8.
- Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, et al. Aliskiren, a human renin inhibitor, amelio- rates cardiac and renal damage in double-transgenic rats. Hypertension 2005;46:569-76.
- Vaidyanathan S, Reynolds C, Yeh CM, Bizot MN, Dieterich HA, Howard D, et al. Pharmacokinetics, safety, and toler- ability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J Clin Pharmacol 2007;47:453-60.
- Uresin Y, Taylor AA, Kilo C, Tschöpe D, Santonastaso M, Ibram G, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combina- tion in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007;8:190-8.
- Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsar- tan in patients with hypertension: a randomised, double- blind trial. Lancet 2007;370:221-9.
- Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007;25:217-26.
- Munger MA, Drummond W, Essop MR, Maboudian M, Khan M, Keefe DL. Aliskiren as add-on to amlodipine provides significant additional blood pressure lowering without increased oedema associated with doubling the amlodipine dose. Eur Heart J Suppl 2006;27:717-84.
Öz
Renal ekstraktlar ile renin anjiotensin sisteminin 1898’de ortaya konmasıyla başlayan tarihi süreci hala şaşırtıcı olmaya devam ediyor. Anjiyotensin dönüştürücü enzim inhibitörleri (ACEI) ve anjiyoten- sin reseptör blokerlerinden (ARB) sonra, son zaman- larda direkt renin inhibitörleri (DRI) de renin anjiyoten- sin alanına girdi. Giderek artan kanıtlarla, renin anji- otensin sistemi inhibisyonu hipertansiyon tadevisinde önemli bir tedavi stratejisidir. Özgün hasta grupları üzerinde ve son organ hasarını korumaya odaklanan sürmekte olan ve gelecekte yapılacak klinik calışma- ların sonuçları, direkt renin inhibisyonu hakkındaki bilgi birikimimizi ve anlayışımızı zenginleştirecektir
Anahtar Kelimeler
Renin anjiyotensin sistemi direkt renin inhibitörleri aliskiren plazma renin aktivitesi.
Kaynakça
- Basso N, Terragno NA. History about the discovery of the renin-angiotensin system. Hypertension 2001;38:1246-9.
- Luft FC. A brief history of renin. J Mol Med 2008;86:611-3.
- Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 2008;7:399-410.
- Siragy HM, Kar S, Kirkpatrick P. Aliskiren: news and analy- sis. Nature Reviews Drug Discovery 2007;6:779-80.
- Uresin Y, Mehtar Bozkurt M, Sabirli S, Ozunal ZG. Aliskiren, the future of renin-angiotensin system blockade? Expert Rev Cardiovasc Ther 2007;5:835-49.
- Müller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006;1:221-8.
- Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocar- dial infarction in hypertensive patients. Am J Hypertens 1997;10:1-8.
- Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, et al. Aliskiren, a human renin inhibitor, amelio- rates cardiac and renal damage in double-transgenic rats. Hypertension 2005;46:569-76.
- Vaidyanathan S, Reynolds C, Yeh CM, Bizot MN, Dieterich HA, Howard D, et al. Pharmacokinetics, safety, and toler- ability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J Clin Pharmacol 2007;47:453-60.
- Uresin Y, Taylor AA, Kilo C, Tschöpe D, Santonastaso M, Ibram G, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combina- tion in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007;8:190-8.
- Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsar- tan in patients with hypertension: a randomised, double- blind trial. Lancet 2007;370:221-9.
- Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007;25:217-26.
- Munger MA, Drummond W, Essop MR, Maboudian M, Khan M, Keefe DL. Aliskiren as add-on to amlodipine provides significant additional blood pressure lowering without increased oedema associated with doubling the amlodipine dose. Eur Heart J Suppl 2006;27:717-84.
Ayrıntılar
| Birincil Dil | Türkçe |
|---|---|
| Bölüm | Makaleler |
| Yazarlar | |
| Yayımlanma Tarihi | 1 Ocak 2010 |
| Yayımlandığı Sayı | Yıl 2010 Cilt: 2010 Sayı: 1 |